BIOEXTRAX AB (85X0) - Total Liabilities
Based on the latest financial reports, BIOEXTRAX AB (85X0) has total liabilities worth €2.11 Million EUR (≈ $2.47 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see BIOEXTRAX AB asset portfolio.
BIOEXTRAX AB - Total Liabilities Trend (2021–2025)
This chart illustrates how BIOEXTRAX AB's total liabilities have evolved over time, based on quarterly financial data. See 85X0 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
BIOEXTRAX AB Competitors by Total Liabilities
The table below lists competitors of BIOEXTRAX AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Txcom SA
PA:ALTXC
|
France | €1.29 Million |
|
Centrex Ltd
AU:CXM
|
Australia | AU$34.09 Million |
|
mVISE AG
XETRA:C1V
|
Germany | €6.96 Million |
|
Spineguard
PA:ALSGD
|
France | €4.07 Million |
|
Yelooo Integra Datanet Tbk PT
JK:YELO
|
Indonesia | Rp8.96 Billion |
|
Tian An Australia Ltd
AU:TIA
|
Australia | AU$188.16 Million |
|
Landmark Property Development Company Limited
NSE:LPDC
|
India | Rs16.77 Million |
|
Vessel Co. Ltd
KQ:177350
|
Korea | ₩17.22 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOEXTRAX AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BIOEXTRAX AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOEXTRAX AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOEXTRAX AB (2021–2025)
The table below shows the annual total liabilities of BIOEXTRAX AB from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.51 Million ≈ $4.11 Million |
+19.61% |
| 2024-12-31 | €2.94 Million ≈ $3.43 Million |
+48.41% |
| 2023-12-31 | €1.98 Million ≈ $2.31 Million |
-67.82% |
| 2022-12-31 | €6.15 Million ≈ $7.19 Million |
+19.60% |
| 2021-12-31 | €5.14 Million ≈ $6.01 Million |
-- |
About BIOEXTRAX AB
Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. The company produces PHA (polyhydroxyalkanoates), a group of bio-based and biodegradable bioplastics that replace fossil-based plastics; PHBV, a stiff, high-performance polymer; and PHO, a soft, flexible, and smooth biopolymer with rubbery properties. It also provides hydrolysates protein for animal feed; … Read more